NCT01092390 is a Phase 3 clinical trial of Lovaza (fish oil) in Diabetes, sponsored by Johns Hopkins University.

Who is sponsoring NCT01092390?

NCT01092390 is sponsored by Johns Hopkins University.

What drugs are being tested in NCT01092390?

Interventions in NCT01092390: Lovaza (fish oil).

Is NCT01092390 still recruiting?

NCT01092390 is currently completed. Last updated 27 April 2012.

Last reviewed 2012-04-27 · How we verify

NCT01092390

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

"Go Fish"Omega-3 Fatty Acid Supplementation in Diabetic Kidney Disease

Completed Phase 3 Last updated 27 April 2012

What this trial tests

Phase 3 trial testing Lovaza (fish oil) in Diabetes in 31 participants. Completed in 1 May 2011.

Timeline

1 March 2010

Primary endpoint
1 May 2011

1 May 2011

Quick facts

Lead sponsor	Johns Hopkins University
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	31
Start date	1 March 2010
Primary completion	1 May 2011
Estimated completion	1 May 2011
Sites	1 location across United States

Drugs / interventions tested

Lovaza (fish oil) — full drug profile →

Conditions studied

Diabetes — all drugs for Diabetes →

Sponsor

Johns Hopkins University

Who can join

21 and older, any sex, with Diabetes. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

urine protein excretion
Time frame: end of 2 six week periods (crossover)
Primary Specific Aim To determine the effects of omega-3 fatty acid supplementation on urine protein excretion and surrogate markers of kidney injury including: serum beta-microglobulin and cystatin C (biomarkers of GFR) and urine neutrophil gelatinase-associated lipocain (NGAL a.k.a. lipocalin-2), kidney injury molecule-1 (KIM-1), and interleukin-18 (IL-18) (biomarkers of tubular reabsorption imp

Sponsor's own description

In this application the investigators describe plans for a randomized controlled cross-over trial to determine the effects of omega-3 fatty acid supplementation on urine protein excretion in 30 adults with diabetes (NIDDM) and kidney disease defined by the presence of proteinuria.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The effects of n-3 long-chain polyunsaturated fatty acid supplementation on biomarkers of kidney injury in adults with diabetes: results of the GO-FISH trial.
Miller ER, Juraschek SP, Anderson CA, Guallar E, et al · · 2013 · cited 42× · PMID 23275364 · DOI 10.2337/dc12-1940

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Johns Hopkins University trials

Trials by the same sponsor.

NCT06236542 — Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety · NA · not yet recruiting
NCT07532252 — Daridorexant for Alcohol Use Disorder · Phase 2 · not yet recruiting
NCT06687655 — Impact of Exogenous Ketones on Sleep Apnea · Phase 1, PHASE2 · not yet recruiting
NCT07079111 — 3D Printed Occlusal Splints for Intraoperative Use · NA · not yet recruiting
NCT02998502 — The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01092390 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
Last refreshed: 27 April 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01092390.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing